Cara Therapeutics, Inc. (CARA)
15.96
-0.69 (-4.14%)
Inactive · Last trade price on Apr 15, 2025

Cara Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
7.147.1420.9741.8723.03135.08
Revenue Growth
-65.96%-65.96%-49.92%81.81%-82.95%579.28%
Gross Profit
-29.25-29.25-92.58-56.14-58.5428.01
Operating Income
-55.78-55.78-121.5-87.54-89.085.39
Net Income
-70.87-70.87-118.51-85.47-88.448.41
Earnings Per Share
-46.60-46.60-78.79-57.36-62.786.39
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
37.937.9100.76156.75236.79251.49
Total Debt
44.4544.4543.171.923.675.28
Net Cash (Debt)
-6.55-6.5557.59154.83233.12246.22
Net Cash Growth
---62.80%-33.58%-5.32%15.14%
Net Cash Per Share
-4.30-4.3038.29103.89165.46184.99

Cash Flow & CapEx

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-60.92-60.92-92.08-78.73-60.09-5.49
Capital Expenditures
-1.05-1.05-2.38-0.04-0.04-0.35
Free Cash Flow
-61.96-61.96-94.45-78.77-60.13-5.84
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Gross Margin
----134.09%-254.19%20.74%
Operating Margin
-781.58%-781.58%-579.43%-209.08%-386.85%3.99%
Pretax Margin
-998.53%-998.53%-565.21%-204.16%-384.06%5.71%
Profit Margin
-992.95%-992.95%-565.21%-204.16%-384.06%6.23%
FCF Margin
-868.19%-868.19%-450.46%-188.15%-261.10%-4.32%

Valuation

Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingJul '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PE Ratio
-----89.65
PS Ratio
3.403.921.9313.7828.285.58